Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Brexanolone injection, the first therapy approved by the US FDA for the treatment of postpartum depression (PPD) in adults, has been shown to produce a significantly greater decrease in the Hamilton Rating Scale for Depression (HAM-D) total score than placebo in randomised controlled trials (RCTs) of women with PPD. OBJECTIVES: Given the rapid effect of brexanolone injection (within 60 h) sustained throughout the length of the trials (30 days), we sought to compare its efficacy data against selective serotonin reuptake inhibitors (SSRIs), the class of antidepressants most commonly prescribed for PPD, using HAM-D and Edinburgh Postnatal Depression Scale (EPDS) outcomes from currently available RCTs. METHODS: We extracted data from 26 studies identified in a systematic literature review of pharmacological and pharmacological/nonpharmacological combination therapies in PPD. Six studies were suitable to form evidence networks through which to perform indirect treatment comparisons (ITCs) of HAM-D and EPDS outcomes between brexanolone and SSRIs. Having assessed the comparability and suitability of the available evidence for analysis, we discovered significant heterogeneity in the study designs, most notably in the placebo arms of the trials. We therefore conducted matching-adjusted indirect comparisons (MAICs) between brexanolone and the placebo arms of comparator studies, subsequently using the MAIC results of brexanolone versus placebo, and results for SSRIs versus placebo, to form ITCs of brexanolone versus SSRIs at three separate time points-day 3, week 4 and last observation. ITCs were calculated as the differences in change from baseline (CFB) in HAM-D and, separately, CFB in EPDS, between treatments, and reported with 95% confidence intervals (CIs). RESULTS: For all time points, MAICs showed larger differences in CFB for brexanolone compared with SSRIs. Differences (95% CIs) between brexanolone and SSRIs were 12.79 (8.04-17.53) [day 3], 5.87 (- 1.62 to 13.37) [week 4] and 0.97 (- 6.35 to 8.30) [last observation] for the HAM-D. For the EPDS, the differences in CFB were 7.98 (5.32-10.64) [day 3], 6.35 (3.13-9.57) [week 4] and 4.05 (0.79-7.31) [last observation]. Other analytical approaches are also presented to demonstrate the similarity of results, using a network meta-analysis approach, and the importance of using the MAIC method to control for the important heterogeneity between placebo arms. CONCLUSIONS: Acknowledging the limitations of ITCs and this evidence base, when compared with SSRIs, these analyses suggest that brexanolone demonstrated larger differences in CFB for both patient- and clinician-reported PPD outcomes and at all investigated time points after adjusting for differences between placebos in the included studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meltzer-Brody, S., Colquhoun, H., Riesenberg, R., Epperson, C. N., Deligiannidis, K. M., Rubinow, D. R., Li, H., Sankoh, A. J., Clemson, C., Schacterle, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31551-4 · Cited by 795
Prevalence of suicidality during pregnancy and the postpartum
Lindahl, V., Pearson, J. L., & Colpe, L. (2005) · Archives of Women’s Mental Health · doi:10.1007/s00737-005-0080-1 · Cited by 795
Hahn-Holbrook, J., Cornwell-Hinrichs, T., & Anaya, I. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00248 · Cited by 667
Goodman, J. H. (2004) · Journal of Advanced Nursing · doi:10.1046/j.1365-2648.2003.02857.x · Cited by 660
Association of persistent and severe postnatal depression with child outcomes
Netsi, E., Pearson, R. M., Murray, L., Cooper, P., Craske, M. G., & Stein, A. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4363 · Cited by 632
Pearson, R. M., Evans, J., Kounali, D., Lewis, G., Heron, J., Ramchandani, P. G., O’Connor, T. G., & Stein, A. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.2163 · Cited by 589
Stewart, D. E., & Vigod, S. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1607649 · Cited by 500
Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.
Kanes, S., Colquhoun, H., Gunduz-Bruce, H., Raines, S., Arnold, R., Schacterle, A., Doherty, J., Epperson, C. N., Deligiannidis, K. M., Riesenberg, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31264-3 · Cited by 479
Cooper, P. J., Murray, L., Wilson, A., & Romaniuk, H. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.5.412 · Cited by 356
Postpartum depression screening: importance, methods, barriers, and recommendations for practice
Gjerdingen, D. K., & Yawn, B. P. (2007) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2007.03.060171 · Cited by 344
Trends in postpartum depressive symptoms- 27 States, 2004, 2008, and 2012
Ko, J. Y., Rockhill, K. M., Tong, V. T., Morrow, B., & Farr, S. L. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6606a1 · Cited by 334
The Course of Postpartum Depression: A Review of Longitudinal Studies
Vliegen, N., Casalin, S., & Luyten, P. (2014) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000013 · Cited by 263
Rojas, G., Fritsch, R., Solis, J., Jadresic, E., Castillo, C., González, M., Guajardo, V., Lewis, G., Peters, T. J., & Araya, R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61685-7 · Cited by 213
Machado-Vieira, R., Salvadore, G., Luckenbaugh, D. A., Manji, H. K., & Zarate, C. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0610 · Cited by 195
Antidepressant treatment for postnatal depression
Molyneaux, E., Howard, L. M., McGeown, H. R., Karia, A. M., & Trevillion, K. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002018.pub2 · Cited by 171 · cited 4×
“For this analysis, the HAM-D was selected as an outcome as it is often recognised as the gold-standard outcome measure in studies of depression [48–51], while the EPDS was chosen as it is more commonly used to screen for PPD in clinical practice and to measure symptom burden [32, 49].”
BackgroundMethodInfluentialYonkers, K. A., Lin, H., Howell, H. B., Heath, A. C., & Cohen, L. S. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0420 · Cited by 98
Chibanda, D., Shetty, A. K., Tshimanga, M., Woelk, G., Stranix-Chibanda, L., & Rusakaniko, S. (2014) · Journal of the International Association of Providers of AIDS Care (JIAPAC) · doi:10.1177/2325957413495564 · Cited by 96
Milgrom, J., Gemmill, A. W., Ericksen, J., Burrows, G., Buist, A., & Reece, J. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414565474 · Cited by 94
Ngai, F.-W., Wong, P. W.-C., Leung, K.-Y., Chau, P.-H., & Chung, K.-F. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000430449 · Cited by 88
Milgrom, J., Holt, C. J., Gemmill, A. W., Ericksen, J., Leigh, B., Buist, A., & Schembri, C. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-95 · Cited by 82
Lilja, G., Edhborg, M., & Nissen, E. (2012) · Scandinavian Journal of Caring Sciences · doi:10.1111/j.1471-6712.2011.00925.x · Cited by 80
Suicidal ideation during the postpartum period.
Bodnar-Deren, S., Klipstein, K., Fersh, M., Shemesh, E., & Howell, E. A. (2016) · Journal of Women's Health · doi:10.1089/jwh.2015.5346 · Cited by 76
Gagliardi, L., Petrozzi, A., & Rusconi, F. (2012) · Archives of Disease in Childhood · doi:10.1136/adc.2009.179697 · Cited by 67
Maternal depression and filicide—case study of ten mothers
Kauppi, A., Kumpulainen, K., Vanamo, T., Merikanto, J., & Karkola, K. (2008) · Archives of Women's Mental Health · doi:10.1007/s00737-008-0013-x · Cited by 56
Metadata
- Authors
- Cooper, M. C., Kilvert, H. S., Hodgkins, P., Roskell, N. S., & Eldar-Lissai, A.
- Venue
- CNS Drugs
- Published
- 2019-10
- Volume
- 33
- Issue
- 10
- Pages
- 1039-1052
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2982055672
- Cited by
- 192
- References
- 24
- FWCI
- 35.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.